PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

UCLB, Apollo secure first licensing deal with US investment powerhouse

UCL Business (UCLB) and Apollo Therapeutics have secured their first out-licensing deal to US healthcare investment firm Deerfield.

The deal will see a novel gene therapy – which originated at UCL and was supported by Apollo, a pioneering collaboration between three global pharmaceutical companies and three UK university technology transfer offices – be further developed in partnership with Deerfield.

Deerfield will leverage its cutting-edge drug development and operational capabilities to advance the translation of biomedical discoveries into transformative treatments for patients.

The firm’s newly launched Cure building in New York City will accelerate this important work, bringing together leading companies in the life science, digital health, medical technology, and health services industries from around the world to uncover innovative solutions to address high-need therapeutic areas.

This is a significant licensing deal for UCLB and Apollo, which was formed in 2016 as a collaborative venture between three world-leading UK universities and AstraZeneca, Glaxo Group Limited and Johnson & Johnson Innovation-JJDC.

“This first licensing deal with Deerfield demonstrates how Apollo can bridge the translational gap from academic research to a product that’s commercially-ready and validates our novel model,” said Dr Richard Butt, Apollo’s chief executive.

“Deerfield is one of the leading investors in life sciences and its backing is testament to the great work by UCL in rare diseases,” added Dr Richard Fagan, director of BioPharm, UCLB and member of Apollo’s Investment Committee.

“Deerfield’s investment is great validation of the Apollo joint venture business model, and demonstrates how UK institutions and its research can attract financing and support from global firms. This deal also demonstrates how universities and industries can work together to mutual commercial benefit, which will be especially important as efforts are made to reboot the global economy.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026